Cefepime and Cefepirome: Key Differences and Clinical Selection
Cefepime is the antibiotic you should use—cefepirome is not FDA-approved in the United States and has limited availability globally, while cefepime has established FDA approval, extensive clinical evidence, and guideline support for multiple indications. 1, 2
Why This Matters
These are both fourth-generation cephalosporins with nearly identical antimicrobial spectra and pharmacokinetic properties, but availability and regulatory approval make cefepime the only practical choice in most clinical settings.
Microbiological Similarities
Both agents demonstrate:
- Comparable in vitro activity against Enterobacteriaceae, with MIC90 values of 0.06-2 mg/L for most species 3
- Enhanced stability against chromosomal AmpC β-lactamases compared to third-generation cephalosporins, due to reduced affinity for β-lactamase and increased outer membrane permeability 4
- Similar activity against Pseudomonas aeruginosa, though cefepime shows slightly better potency (MIC90: 16 mg/L) 3
- Equivalent pharmacokinetics in critically ill patients, with drug clearance primarily dependent on creatinine clearance rather than the specific agent 5
Critical Pharmacokinetic Consideration
Both drugs exhibit significant inoculum effects against ESBL-producing organisms, particularly SHV-type producers. At high bacterial loads (10^7 CFU/mL), resistance emerges despite susceptible MICs at standard inocula 6. This means:
- Standard disk diffusion testing may miss resistance, especially for cefepime
- Deep-seated infections with high bacterial burdens require careful consideration
- Neither agent should be used for confirmed ESBL producers despite in vitro susceptibility
FDA-Approved Indications for Cefepime
Cefepime is indicated for 1, 2:
- Moderate to severe pneumonia (including P. aeruginosa): 1-2g IV q8-12h
- Febrile neutropenia (empiric monotherapy): 2g IV q8h for 7 days
- Complicated/uncomplicated UTI and pyelonephritis: 0.5-2g IV/IM q12h depending on severity
- Uncomplicated skin/soft tissue infections: 2g IV q12h
- Complicated intra-abdominal infections (with metronidazole): 2g IV q8-12h
Guideline Support for Cefepime
For AmpC-producing Enterobacterales infections, recent evidence shows:
- Cefepime demonstrates non-inferior mortality compared to carbapenems for bloodstream infections 7
- However, for deep-seated infections (abscesses, osteomyelitis, endocarditis), carbapenems show lower adjusted odds of clinical failure (aOR 0.44,95% CI 0.29-0.83) 8
- Avoid cefepime for third-generation cephalosporin-resistant Enterobacterales per ESCMID guidelines 9
Clinical Algorithm for Selection
Use cefepime when:
- Treating empiric febrile neutropenia
- Confirmed susceptible P. aeruginosa infections
- AmpC-producing Enterobacterales bloodstream infections (non-deep-seated)
- Moderate-severe pneumonia requiring Gram-negative coverage
Switch to carbapenem when:
- Deep-seated AmpC infections (abscesses, bone/joint, endocarditis)
- Third-generation cephalosporin resistance confirmed
- ESBL producers (regardless of cefepime MIC)
- Clinical failure on cefepime after 48-72 hours
Critical Dosing Pitfall
54% of ICU patients have antibiotic levels below MIC for >20% of the dosing interval despite normal creatinine, because 34% have creatinine clearance >144 mL/min 5. For critically ill patients:
- Measure creatinine clearance, not just serum creatinine
- Consider q8h dosing instead of q12h if CrCl >120 mL/min
- Extended or continuous infusions optimize time above MIC
Bottom Line
Cefepirome is essentially unavailable—use cefepime. When treating AmpC-producing organisms, cefepime works for bloodstream infections but carbapenems are superior for deep-seated infections. Always calculate actual creatinine clearance in critically ill patients to avoid underdosing.